Glusod

Glusod is an oral prescription medication that contains the active ingredient empagliflozin, a sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor. It is marketed in the European Union and is supplied as a tablet (strength not specified). Empagliflozin works by reducing renal glucose reabsorption, leading to increased urinary glucose excretion, which helps lower blood glucose levels in adults with type 2 diabetes, and is typically prescribed as part of a comprehensive diabetes management plan.

Glusod (empagliflozin) is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, often in combination with diet and exercise.

- As monotherapy when metformin is contraindicated or insufficient. - Combined with metformin when additional glycemic control is needed. - Used with other antihyperglycemic agents such as DPP‑4 inhibitors, GLP‑1 receptor agonists, or insulin. - May be considered in patients with established cardiovascular disease to reduce risk of cardiovascular death. - Occasionally prescribed for off‑label renal protection under specialist supervision (note: off‑label use varies by jurisdiction).

The safety profile of Glusod reflects the pharmacology of SGLT2 inhibition; side effects are reported across clinical studies and post‑marketing experience.

Common: - Increased urinary frequency and volume, which may lead to nocturia. - Genital yeast infections, particularly vulvovaginal candidiasis in women and balanitis in men. - Mild to moderate urinary tract infections presenting with dysuria or urgency. - Sensations of thirst or dry mouth, often related to osmotic diuresis.

Serious: - Euglycemic diabetic ketoacidosis, a rare but potentially life‑threatening metabolic complication. - Acute kidney injury or a rapid decline in renal function, especially in patients with pre‑existing kidney disease. - Severe dehydration or hypotension resulting from excessive fluid loss.

When prescribing Glusod, clinicians should evaluate patient-specific factors and monitor for conditions that may be aggravated by SGLT2 inhibition.

- Assess renal function; avoid use in patients with eGFR below the approved threshold. - Monitor for signs of volume depletion, especially in the elderly or those on diuretics. - Evaluate risk of genital infections and counsel on hygiene measures. - Review concomitant use of insulin or insulin secretagogues to prevent hypoglycemia. - Consider ketoacidosis risk in patients with low carbohydrate intake or acute illness. - Use caution during pregnancy or lactation; safety data are limited.

Glusod may interact with other medicines that affect glucose control, renal function, or fluid balance, requiring dose adjustments or monitoring.

Avoid: - Concomitant use with strong SGLT2 inhibitors or dual SGLT1/2 inhibitors, which can amplify glucose loss and dehydration. - Combining with high‑dose loop diuretics in patients at risk of hypotension.

Use with caution: - Insulin or sulfonylureas, as additive hypoglycemia risk may require dose reduction. - NSAIDs or ACE inhibitors that may affect renal perfusion. - Anticoagulants, because dehydration could alter drug concentration. - Alcohol, which can increase the risk of ketoacidosis.